Latest PharmAthene Inc. Stories
ANNAPOLIS, Md., May 30, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on a proposed Phase II study of SparVax(®), a next generation recombinant anthrax vaccine. "We are very pleased by the FDA's thorough review of the SparVax(® )stability data and its subsequent...
Delaware High Court Confirms Availability of Expectancy Damages ANNAPOLIS, Md., May 26, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) today announced that the Delaware Supreme Court upheld the earlier ruling that SIGA breached its contractual obligation to negotiate in good faith. The Court has remanded the case to the Delaware Court of Chancery for further reconsideration of the damages award, consistent with its opinion. "We are pleased by this positive decision from the...
ANNAPOLIS, Md., May 8, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial and operational results for the first quarter of 2013. "We made steady progress in our biodefense programs this quarter," said Eric I. Richman, President and Chief Executive Officer. "We submitted to the U.S. Food and Drug Administration (FDA) our complete response to the...
ANNAPOLIS, Md., May 6, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that its financial and operating results for the first quarter of 2013 will be released on Wednesday, May 8, 2013. PharmAthene management will host a conference call to discuss the Company's first quarter 2013 financial and operational results. The call is scheduled to begin at 4:30 pm Eastern...
Nerve Agents Including Sarin and Tabun are Believed to be Part of the Syrian Chemical Weapons Inventory ANNAPOLIS, Md., April 17, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Army Medical Research Institute for Chemical Defense has completed initial in vitro testing of the Company's recombinant butyrylcholinesterase (rBChE) bioscavenger...
ANNAPOLIS, Md., March 13, 2013 /PRNewswire/ -- Year-End 2012 Highlights Received favorable final order and judgment from Delaware Chancery Court against SIGA Technologies Accelerated funding for bioscavenger program under Department of Defense contract Strengthened financial position and secured $7.5 million credit facility Achieved 70% year-over-year reduction in operating cash usage PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures...
ANNAPOLIS, Md., March 12, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2012 will be released on Wednesday, March 13, 2013. PharmAthene management will host a conference call to discuss the Company's year-end financial and operational results beginning at 4:30 p.m. Eastern Time on Wednesday, March 13,...
ANNAPOLIS, Md., Jan. 17, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Noble Financial Capital Markets Ninth Annual Equity Conference on Tuesday, January 22, 2013 at 9:30 a.m. ET in Room 1 at the Hard Rock Hotel, Hollywood, Florida. Mr. Richman and Linda Chang, Senior Vice President...
ANNAPOLIS, Md., Jan. 10, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced that the Delaware Supreme Court heard oral arguments today related to both parties' appeal in the Company's on-going litigation against SIGA Technologies. SIGA appealed the final judgment in favor of PharmAthene issued by the Delaware Court of Chancery on May 31, 2012, in which PharmAthene was awarded 50% of the net profits over a period of ten years from all sales of SIGA's smallpox antiviral...
ANNAPOLIS, Md., Nov. 6, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial results for the third quarter ended September 30, 2012. President and Chief Executive Officer, Eric I. Richman, said, "We made steady progress in the third quarter toward meeting our objectives. Most importantly, we have worked expeditiously to address the U.S. Food...
